- Senior Editor, Cancer – Volume One e-Book, Cancer Volume Two
- Senior Editor, Genomics – Volume One e-Book, Genomics Volume Two
- Content Consultant, Series A: Cardiovascular, Volume One – Nitric Oxide
- EAW for the following Research Categories:
- Cell Biology and Cell Circuits
- Chemical Biology and its relations to Metabolic Disease
- Disease biology, using small molecules toward the development of therapeutic drugs.
- Cancer Biology and Innovations in Cancer Therapy
STEPHEN J. WILLIAMS, Ph.D.
Tel: 215 487 0259 (h) 610 331 1016 (c) Email: email@example.com
a biochemical pharmacologist with expertise in translational research and mechanistic studies of ovarian cancer and of various pathologies. My recent research has involved numerous aspects regarding ovarian cancer including mechanisms of cisplatin resistance, molecular and environmental changes involved in ovarian oncogenesis, and development of cell-based assays and animal models for research of and preclinical drug evaluation in ovarian cancer, abilities that are easily translated to other tumor types. I have also patented a porcine model of ovarian cancer, useful for testing the safety and efficacy of adenoviral gene therapies, and written and received grants and research contracts. My experience in the multiple disciplines of pharmacology, toxicology, physiology, biochemistry, and molecular biology has provided unique perspective and skill in my study of cancer and other disease. In addition, I have the ability to work as a strong team player and additionally excel working independently with sharp computational skills.
AREAS OF EXPERTISE
- Molecular Biology and Biochemistry: Transitional research, recombinant DNA technologies; RNA/DNA purification and analysis; real-time PCR and primer design; DNA methylation; Western analysis (quantative); ELISA; DNA repair assays; enzyme kinetics; analysis of cellular redox status; protein modification; enzyme and protein purification; column chromatography; HPLC; immunohistochemistry; reporter gene assays.
- Cellular: Primary cell culture and isolation; development and establishment of cell lines (primary and tumorigenic, stable lines generation); flow cytometry; Guava single cell analysis; soft agar colony assay; cell proliferation/toxicity assays; in-vitro transformation.
- In-Vivo: Small animal handling and colony maintenance; development of animal models of ovarian cancer; in-vivo preclinical drug evaluation; necropsy and gross pathology; small animal imaging.
PUBLICATIONS with Leaders in Pharmaceutical Business Intelligence
Volume One: Perspectives on Nitric Oxide
Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Aviral Vatsa, PhD and Content Consultant: Stephen J Williams, PhD
Series B: e-Books on Genomics & Medicine
Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015
Sr. Editor: Larry Bernstein, MD, FCAP, Editor: Stephen J Williams, PhD
Series C: e-Books on Cancer and Genomics
Editors: Stephen J Williams, PhD, Dror Nir, PhD and Tilda Barliya, PhD, Ritu Saxena, PhD
PUBLICATIONS in Open Access Online Scientific Journal
Williams, S.J. July 1, 2014. Good and Bad News Reported for Ovarian Cancer Therapy
Williams, S.J. June 17, 2014. Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification.
Williams, S.J. June 11, 2014. The SCID Pig II: Researchers Develop Another SCID Pig, And Another Great Model For Cancer Research
Williams, S.J. May 6, 2014. The Cancer Research Concentration @ Leaders in Pharmaceutical Business Intelligence
Williams, S.J. April 4, 2014. Heroes in Medical Research: Developing Models for Cancer Research
Williams, S.J. January 3, 2014. Loss of Gene Islands May Promote a Cancer Genome’s Evolution: A new Hypothesis on Oncogenesis
Williams, S.J. November 23, 2013. Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors
Williams, S.J. October 11, 2014. The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research
Williams, S.J. September 4, 2013. Issues in Personalized Medicine: Discussions of Intratumor Heterogeneity from the Oncology Pharma forum on LinkedIn
Williams, S.J. August 7, 2013. Nitric Oxide Mitigates Sensitivity of Melanoma Cells to Cisplatin
Williams, S.J. June 13, 2013. Combining Nanotube Technology and Genetically Engineered Antibodies to Detect Prostate Cancer Biomarkers
Williams, S.J. May 30, 2013. New scheme to routinely test patients for inherited cancer genes
Williams, S.J. April 17,2013. Heroes in Medical Research: Dr. Robert Ting, Ph.D. and Retrovirus in AIDS and Cancer
Williams, S.J. March 13, 2013. Personalized Medicine: Clinical Aspiration of Microarrays
Williams, S.J. March 12, 2013. AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Williams, S.J. February 10, 2014. Rewriting the Mathematics of Tumor Growth; Teams Use Math Models to Sort Drivers from Passengers
Williams, S.J. February 3, 2013. Genome-Wide Detection of Single-Nucleotide and Copy-Number Variation of a Single Human Cell
Williams, S.J. January 12, 2013. Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin
Williams, S.J. January 3, 2013. Differentiation Therapy – Epigenetics Tackles Solid Tumors
Williams, S.J. November 30, 2012. Prostate Cancer Cells: Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition
Williams, S.J. October 31, 2012. How Mobile Elements in “Junk” DNA Promote Cancer – Part 1: Transposon-mediated Tumorigenesis
Williams, S.J., reporter, June 19, 2014. Second Annual Single-Cell Sequencing of Cancer Rountable August 20,21, 2014 Washington DC
Williams, S.J. March 27, 2013. Ethical Concerns in Personalized Medicine: BRCA1/2 Testing in Minors and Communication of Breast Cancer Risk
Williams, S.J. November 20, 2012. FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules
Williams, S.J. November 7, 2012. Report on the Fall Mid-Atlantic Society of Toxicology Meeting “Reproductive Toxicology of Biologics: Challenges and Considerations:
Williams, S.J. October 29, 2013. Heroes in Medical Research: Dr. Carmine Paul Bianchi Pharmacologist, Leader, and Mentor
Williams, S.J. February 24, 2013. Mobilizing Scientific Societies: Editorial by Science Editor-in-Chief Dr. Bruce Alberts
Williams, S.J. September 24, 2012. Nitric Oxide Covalent Modifications: A Putative Therapeutic Target?
Williams, S.J. May 14, 2014. The Bioscience Crowdfunding Environment: The Bigger Better VC?
Williams, S.J. February 24, 2014. Tycho Brahe, where art thou? Today’s Renaissance of the Self-Funded Scientist!
Williams, S.J. May 15, 2013. Finding the Genetic Links in Common Disease: Caveats of Whole Genome Sequencing Studies
(6/2016 – Present)
Fox Chase Cancer Center, Philadelphia, PA
RESEARCH ASSOCIATE – Dept of Medical Oncology
(laboratory PI Thomas C. Hamilton)
Developed innovative protocols in ovarian cancer research to determine mechanisms of altered vitamin A metabolism in ovarian cancer and resultant effects on tumorigenicity and ovarian cancer stem cell phenotype. Secured significant funding for multiple projects by identifying resources and submitting intelligent and accessible grant requests. Developed and patented a porcine model of ovarian cancer, useful for testing the safety and efficacy of adenoviral gene therapies. Developed human ovarian tumor surrogate marker for corporate preclinical drug study. Wrote and awarded two internal grants as Co-Principal Investigator.
Discovered the molecular mechanisms by which alteration of vitamin A metabolism, CRBP1 expression and redox status alters the tumorigenic phenotype of ovarian cancer using novel cell culture, inducible mouse models and molecular analysis. Work resulted in three peer-reviewed publications, one review and one international meeting abstract.
Determined the mechanism of complete loss of vitamin A metabolism in human ovarian cancer via complete loss of ALDH1A2 in human ovarian cancer specimens
Developed human ovarian tumor surrogate marker for preclinical drug study for Corporation (2 awarded funding agreements). Provided excellent liaison with multi-tier personnel in both industry, clinical and scientific community throughout project timeline.
Designed novel porcine ovarian cancer model for collaborative project with University of Alabama, Birmingham
Collaborated in studies showing utility of MRI in evaluating chemotherapy response in GEM ovarian tumor model
Fox Chase Cancer Center, Philadelphia, PA.
POSTDOCTORAL ASSOCIATE – Dept. of Medical Oncology
(laboratory PI Thomas C. Hamilton)
Discovered that decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. Conducted research on a diversity of multiple funded projects in ovarian cancer research including mechanisms of cisplatin resistance, molecular and environmental changes involved in ovarian oncogenesis, and development of cell-based assays and animals models.
Translated findings of CRBP1 loss in rat ovarian cancer model to human ovarian cancer via by developing real-time PCR protocols.
Determined importance of AKT signaling toward p21 expression and DNA damage response after cisplatin/paclitaxel exposure in sensitive/resistant ovarian cancer cell lines
Discovered complete loss of CRBP1 expression in cohorts of micro-dissected human ovarian cancer tissues using real-time PCR.
Findings led to successfully funded RO1, three peer-reviewed publications, one book chapter and four meeting abstracts.
Keen leadership of laboratory team including handling of laboratory safety.
Assisted in grant, report and manuscript preparation.
Institute for Environmental Medicine, University of Pennsylvania
Conducted thorough investigation on cell signaling mechanisms involved in surfactant secretion from pulmonary type II pneumocytes after environmental changes.
Cell isolation and culture of primary rat type II pneumocytes; isolated lung perfusion model.
Research resulted in three meeting abstracts.
Cytogen Corporation, Princeton, NJ.
Provided efficient performance following strict protocols in dosing of mice and laboratory duties for various research experiments including detailed observation reporting/monitoring and result translation. Performed offsite laboratory set up adhering to strict guidelines for safety and efficacy.
PHARMACOLOGY RESEARCH ASSISTANT INTERN
Created protocols, optimized experimental conditions and conducted experiments in the investigation of effects of leukotriene antagonist on gallbladder and atrial contraction in guinea pigs.
Doctor of Philosophy (Ph.D) in Pharmacology
Temple University School of Medicine, Philadelphia, PA September 1998
Bachelor of Science in Toxicology
Philadelphia School of Pharmacy and Science, Philadelphia, PA May 1988
U.S. Provisional Patent # 0149-PO464US01: Patent application title: Cancer Compositions, Animal Models, and Methods of Use Thereof. Development of a porcine model of epithelial ovarian cancer.
AWARDS AND HONORS
NIH Pharmacology Research and Training Fellowship, Fox Chase Center, 1998
Doctoral Dissertation Research Award, Temple University, 1998
NCI Training Grant, Temple University, 1994-1996
University Fellowship, Temple University, 1990-1992
Teaching and Mentoring & Professional Services
Medical Pharmacology ( Temple University ): Designed and conducted reviews for medical student for chemotherapeutic and cardiac therapeutics; designed quizzes for chemotherapy and metal toxicology sections
Mentored High School teacher in laboratory techniques
Mentored High School teacher in MASOT sponsored program
Mentored Middle School student in design, conduct and presentation for school science fair – won first prize. Event sponsor Fox Chase Cancer Center.
Clinical Cancer Research
Mid-Atlantic Society of Toxicology
Mid-Atlantic Society of Pharmacology
American Association for the Advancement of Science
AALAS Animal Technician
EPA Region III Pennsylvania – Asbestos Abatement Supervisor
1. Cvetkovic, D. and Williams, S.J. Ovarian preneoplasia. In: A. Nasir, S.C. Rubin, and G.P. Sutton (eds.), Preneoplastic Changes, Springer, Dordrecht, The Netherlands (in press).
2. Williams, S. J., Cvetkovic, D., Hamilton, T. C. Vitamin A Metabolism is Impaired in Human Ovarian Cancer. Gynecologic Oncology, 112: 637-645, 2009.
3. Cvetkovic, D. and Williams, S.J. Are there precursor lesions for ovarian cancer: a review. Serbian Archives of Medicine, 136(Suppl 1): 48-53, 2008.
4. Hensley, H., Quinn, B.A., Wolf, R.L., Litwin, S.L., Mabuchi, S., Williams, S.J., Williams, C., Hamilton, T.C., Connolly, D.C. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer. Cancer Biology and Therapy, 6(11): 1717-1725, 2007.
5. Cvetkovic, D., Williams, S.J., and Hamilton, T.C.Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. Clinical Cancer Research, 9: 1013-1020, 2003.
6. Roberts, D., Williams, S.J., Cvetkovic, D., Weinstein, J.K., Godwin, A.K., Johnson, S.W., and Hamilton, T. C. Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. DNA and Cell Biology, 21: 11-19, 2002.
7. Williams, S.J., and Hamilton, T.C. Chemotherapeutic resistance in ovarian cancer. In: S.C. Rubin, and G.P. Sutton (eds.), Ovarian Cancer, pp.34-44. Lippincott, Wilkins, and Williams, New York, 2000.
8. Mitsuuchi, Y., Johnson, S.W., Selvakumaran, M., Williams, S.J., Hamilton, T.C., and Testa, J.R. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21 waf1/dip1/sdIl induced by Cisplatin and Paclitaxel. Cancer Research 60: 5390-5394, 2000.
9. Williams, S.J., and Sirover, M.A. Mechanisms of Nitric Oxide-Protein Interactions: Species Specific NO-NAD+ Modification and Kinetic Alteration of the Glycolytic Protein Glyceraldehyde 3-Phosphate Dehydrogenase. Temple University Press, 1999.
Cvetkovic, D., Williams, S. J., Hamilton, T. C. Loss of vitamin A metabolism in ovarian cancer. 19th Meeting of the European Association for Cancer Research, Budapest, Hungary, 2006.
Williams, S.J., Cvetkovic, D., and Hamilton, T. C. Retinol conversion is impaired in human ovarian cancer cell lines relative to normal surface epithelial cells. 95th Annual Meeting of the AACR, Orlando, FL, 2004.
Cvetkovic, D., Williams, S.J., and Hamilton, T.C. Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. 10th SPORE Investigators’ Workshop, Chantilly, VA, 2002.r
Cvetkovic, D., Williams, S.J., and Hamilton, T.C. Expression of cellular retinol-binding protein 1 is decreased in human ovarian cancer. 93rd Annual Meeting of the AACR, San Francisco, CA, 2002.
Cvetkovic, D., Williams, S.J., and Hamilton, T.C. Validation of real-time RT-PCR detection of cellular retinol-binding protein 1 expression in human ovarian cancer. 9th SPORE Investigators’ Workshop, Washington, DC, 2001.
Sen, N., Williams, S.J., and Chander, A. Secretion of phosphotidylcholine from lung epithelial type II cells in primary culture is inhibited by anion exchange inhibitors. FASEB, 1991.
Chander, A., and Williams, S.J. Alkalosis stimulates surfactant secretion and protein phosphorylation in lung epithelial type II cells. World Conference on Lung Health, 1990.
Chinoy, M.R., Williams, S.J., Dodia, C., and Fisher, A.B. Matrix influences lung surfactant uptake by primary cultures of adult rat granular pneumocytes. ASCB meeting, 1990
Completed Grants/Written and Co-written
Fox Chase Cancer Center Grant Supported Pilot Project: “Sleeping Beauty Based Ovarian Cancer Gene Discovery”;10/2010-09/2011; Co-Investigator
SPORE (Specialized Program in Ovarian Cancer Research Excellence) Pilot Project: “Noncanonical Roles of CRBP1 in Ovarian Oncogenesis”; 08/2009-07/2010; Co-Investigator
Research Funding Agreements(2) for preclinical evaluation of antibody-based therapy in an in-vivo model of human ovarian cancer; 2009-2011 Co-P.I.
Assisted in writing of a successful NIH RO1 CA107195; Loss of Vitamin A Metabolism in Ovarian Oncogenesis; P.I. Thomas C. Hamilton; 06/2005 – 04/2010